- Conditions
- Metastatic Colon Cancer
- Interventions
- Curcumin, 5-flurorouracil
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,153
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gastrointestinal Cancer
- Interventions
- Oxaliplatin, Capecitabine, Leucovorin, 5-fluorouracil, radiation
- Drug · Radiation
- Lead sponsor
- Tannaz Armaghany
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Houston, Texas
- Conditions
- Esophageal Cancer
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
- Conditions
- Advanced or Metastatic Colorectal Cancer
- Interventions
- Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, semaxanib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 26
- States / cities
- Montgomery, Alabama • Arcadia, California • La Jolla, California + 22 more
- Conditions
- Peritoneal Neoplasms
- Interventions
- Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX
- Procedure · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Cancers
- Interventions
- HAI Oxaliplatin, 5-FU, Bevacizumab, Cetuximab, Leucovorin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rectal Cancer
- Interventions
- M1 scheme, standard long course chemoradiotherapy
- Other
- Lead sponsor
- University Medical Center Groningen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Unresectable Metastatic Colorectal Cancer
- Interventions
- CYAD-101, FOLFOX, Pembrolizumab
- Drug
- Lead sponsor
- Celyad Oncology SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Tampa, Florida
- Conditions
- Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Interventions
- Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 16 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Abraxane, FOLFIRINOX, Chemoradiation
- Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anus Neoplasms
- Interventions
- Proton therapy, Chemotherapy
- Radiation · Drug
- Lead sponsor
- Jordan Kharofa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Cancer
- Interventions
- HistoSonics Edison® System, Chemotherapy
- Device · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, Bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Solid Tumor
- Interventions
- Cetuximab, Cisplatin, 5 - Fluorouracil
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more
- Conditions
- Head and Neck Cancer
- Interventions
- Induction chemotherapy, cisplatin, fluorouracil, low-LET cobalt-60 gamma ray therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Colorectal Neoplasms, Diarrhea
- Interventions
- PHY906
- Drug
- Lead sponsor
- PhytoCeutica
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 3
- States / cities
- West Haven, Connecticut • New York, New York • Greenville, South Carolina
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 783
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more
- Conditions
- Pancreatic Cancer
- Interventions
- Onvansertib, NALIRIFOX
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- GastroEsophageal Cancer, Colorectal Cancer
- Interventions
- etrumadenant, mFOLFOX
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
- Conditions
- Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Interventions
- Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • St Louis, Missouri • Nashville, Tennessee